Since
resveratrol is not a potent cytotoxic compound when compared with other chemotherapeutic agents, several previous studies have been performed to obtain synthetic analogs of
resveratrol with potent activity. Our previous study demonstrated that the
resveratrol analog
HS-1793 showed stronger antitumor activity than
resveratrol in various
cancer cells. We examined the antitumor activity exerted by
HS-1793 in
prostate cancer cells, and we observed that
HS-1793 acts as a
polyploidy inducer. Noticeably, multinucleation and polyploidization were induced in most LNCaP cells treated with
HS-1793 at the dose causing a slight decline in cell viability. However, the induction of multinucleation and polyploidization was much lower in PC-3
prostate cancer cells treated with the same dose of
HS-1793. Western blot and RT-PCR analyses showed that the expression of Aurora B was almost undetectable in LNCaP cells, but it was highly expressed in PC-3 cells. Further, silencing of Aurora B sensitized PC-3 cells to HS-1793-induced multi-nucleation. These results indicate that expression of Aurora B determines multinucleation in
prostate cancer cells treated with
HS-1793. Additional assays using multiple
cancer cell lines show that the population of multinucleated cells induced by
HS-1793 treatment is inversely proportional to Aurora B expression. We further elicited that the HS-1793-induced
polyploid LNCaP cells are vulnerable to downregulation of Bcl-xL. Since the polyploidization in LNCaP induced by
HS-1793 does not appear to cause definite commitment to apoptosis, the termination of
polyploid cells by inhibition of Bcl-xL could provide an advantageous means to improve chemotherapeutic efficacy of
HS-1793.